Company Analysis
Sign in

Abivax SA (ABVX)

Nasdaq: ABVX · Pharmaceutical Preparations · Paris · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.7
◀ Past 5.1● Present 5.3▶ Future 6.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-€336M-90.7%
Earnings per share€-4.83-72.5%
Operating cash flow-€161M-4.6%
Cash€517M+258.3%
Debtn/a
Shareholders’ equity€455M+1021.6%
Shares, diluted69.5M+10.3%
Return on equity-73.8%
The recordfrom its filings
Filings in 202626
Newest filingSep 21 · 6-K
Annual reportMar 23, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted38
Filer categoryAccelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
2122232425
As filed, in EUR. Nothing here is a forecast.

News

Sep 21, 2026 · SEC EDGAR · Form F-6EF
Form F-6EF
Open the filing on sec.gov
Jul 2, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Jun 30, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ABVX · research, not advice